6th International Meeting on Aortic Diseases

New insights into an old problem

CHU Liège, APF

September 12-14 2018

Les Comtes de Méan Liège, Belgium

www.chuliege-imaa.be
6th International Meeting on Aortic Diseases
New insights into an old problem
September 12-14, 2018 • Liège • Belgium

W e are really honored to announce the sixth edition of the International Meeting on Aortic Diseases that is organized from September 12 to 14, 2018 in Liège, Belgium.

Once again, the main goal of the International Meeting on Aortic Diseases (IMAD) is to gather all cardiovascular clinicians and scientists to share their experiences on basic research, genetic aspects of aortic aneurysms, aortic dissections, aortic graft infection and their treatment as well as on the new pathological concepts in bicuspid aortic valve, TAVI indications and surgical treatment of aortic valve diseases and also, to provide information about the latest innovations in spinal cord protection.

You are a vascular or a cardiac surgeon, you are a radiologist, a cardiologist, a geneticist, a biologist, an epidemiologist and/or any scientist, you are welcome in Liège where you’ll have the opportunity to share the experiences of the most renowned experts on aortic diseases. During our “Ask to experts” sessions, you can discuss your challenging cases and also receive answers from them to any question you would have.

We look forward to welcoming you in Liège and to sharing from them to any question you would have.

In Liège where you'll have the opportunity to share the experiences of all cardiovascular clinicians and scientists to share their experiences on basic research, genetic aspects of aortic aneurysms, aortic dissections, aortic graft infection and their treatment as well as on the new pathological concepts in bicuspid aortic valve, TAVI indications and surgical treatment of aortic valve diseases and also, to provide information about the latest innovations in spinal cord protection.

You are a vascular or a cardiac surgeon, you are a radiologist, a cardiologist, a geneticist, a biologist, an epidemiologist and/or any scientist, you are welcome in Liège where you’ll have the opportunity to share the experiences of all cardiovascular clinicians and scientists to share their experiences on basic research, genetic aspects of aortic aneurysms, aortic dissections, aortic graft infection and their treatment as well as on the new pathological concepts in bicuspid aortic valve, TAVI indications and surgical treatment of aortic valve diseases and also, to provide information about the latest innovations in spinal cord protection.

Natzi Sakalihasan and Jean-Olivier Defraigne

Under the patronage of:

- University of Liège
- Cardiovascular Surgery Department of CHU of Liège
- Province of Liège
- APF (Aneurysmal Pathology Foundation)
- Faculty of Medicine, ULg

Course Director:
Natzi SAKALIHASAN
Liège, Belgium

Co-Director:
Jean-Olivier DEFRAIGNE
Liège, Belgium

Scientific Committee:
Marc BAILEY
Leeds, United Kingdom
Alessandro DELLA CORTE
Napoli, Italy
John ELEFTERIADES
New Haven, USA
Rebecca HULTGREEN
Stockholm, Sweden
Patrizio LANCELLOTTI
Liège, Belgium
Nicos LABROPULOS
Stony Brook, USA
Christoph NIENABER
London, United Kingdom
Florence PINET
Lille, France
Marc RADERMECKER
Liège, Belgium

Eric ALLAIRE
Clercy, France
Parla ASTARCI
Brussels, Belgium
Marc BAILEY
Leeds, United Kingdom
Jean-Pierre BECUQUEMIN
Champigny, France
Colin BICKNELL
London, United Kingdom
Thomas BILFINGER
New York, USA
Malenka BISSELL
Oxford, United Kingdom
Simon BODDY
Boston, USA
Evelyne BOESEMS
London, Belgium
Matthew BOWN
Leicester, United-UK
Christine BROSTJAN
Vienna, Austria
Jan BRUNKWALL
Köln, Germany
Albert BUSCH
Munich, Germany
Raphael COSCAS
Boulogne Billancourt, France
Audrey COURTOIS
Liège, Belgium
Ronald DALMAN
Stanford, USA
Lazar B. DAVIDOVIC
Belgrade, Serbia
Julie DE BACKER
Gen, Belgium
Jean-Olivier DEFRAIGNE
Liège, Belgium
Alessandro DELLA CORTE
Napoli, Italy
Ruggiero DE PAOLIS
Rome, Italy
Nimish DESAI
Philadelphia, USA
Vincent D’ORIO
Lier, Belgium
Barry DOYLE
Perth, Australia
Rodolphe DURIEUX
Liège, Belgium
Harald EINEM
Munich, Germany
Wolf Hans EILENBERG
Vieno, Austria
John ELEFTERIADES
New Haven, USA
Per ERIKSSON
Stockholm, Sweden
Christian GASSER
Stockholm, Sweden
Athanasios GIANNOUKAS
Larnaca, Greece
Evdas GIRDASUKAS
Hamburg, Germany
Jonathan GOLLEDGE
Townsville, Australia
Franco GREGO
Padova, Italy
Nimrat GREWAL
Leiden, Netherlands
Robin HEIJMEN
Nieuwveld, Netherlands
Rebecka HULTGREEN
Stockholm, Sweden
Bernard IUNG
Paris, France
Ramanan JASHARI
Barcelona, UK
Joëlle KEFER
Louvain, Belgium
Arnaud KERZMANN
Lille, Belgium
Luca KOECHLIN
Basel, Switzerland
Tilo KÖLBEL
Hamburg, Germany
Fabien KOSKAS
Paris, France
Nicholas T. KOUCHOUKOS
London, UK
Nicos LABROPULOS
Stony Brook, USA
Patrizio LANCELLOTTI
Liège, Belgium
Jean-Paul LAVIGNE
Liège, Belgium
Christos LIAPIS
Athens, Greece
Jon LINDEMAN
Leiden, Netherlands
Jes LINDHOLT
Odense, Denmark
Bart LOYS
Antwerp, Belgium
Lars MAEGDEFESSEL
Stockholm, Sweden
Christina MARTINEZ
Lier, Belgium
Hector MICHELENA
Rochester, USA
Dianna MILIEWICZ
Houston, USA
Bijan MODARAI
London, United Kingdom
Thomas MODINE
Lond, France
Firas MUSSA
New York, USA
Alain NHIMI LONGANG
Liège, Belgium
Christoph NIENABER
London, United Kingdom
Joel PINCEMAIL
Liège, Belgium
Florence PINET
Lille, France
Janet POWELL
London, United Kingdom
Cesare QUARTO
London, United Kingdom
Mark RADERMECKER
Liège, Belgium
Ulrich ROSENDAHL
London, UK
Joy ROY
Stockholm, Sweden
Natzi SAKALIHASAN
Liège, Belgium
Athanasios SARATZIS
Leicester, United Kingdom
Igor SINCOS
Rio de Janeiro, Brazil
Toru SUZUKI
Leicester, United Kingdom
Sverker SVENSOJ
Uppsala, Sweden
Apostolos TASSIOPOULOS
Stony brook, USA
Vincent TCHANA-SATO
London, UK
Mathias THIELMANN
Essen, Germany
Ramesh TRIPATHI
London, United Kingdom
Angela UEBING
London, United Kingdom
Rao VALLABHANENI
Liverpool, United Kingdom
Aline VERSTRAETEN
Antwerp, Belgium
Emiliano VOTTA
Milan, Italy
Anders WANHAIEN
Uppsala, Sweden
Kakhtee YEUNG
Amsterdam, Netherlands
Koichi YOSHIMURA
Vamapsuchi, Japan
Clark ZEEBREGTS
Brongenisse, Netherlands
Bulat ZIGANSHIN
New Haven, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Wednesday September 12</th>
<th>Thursday September 13</th>
<th>Friday September 14</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>What’s new in research on bicuspid aortopathy?</td>
<td>08.30</td>
<td>Epidemiology and natural history of AAA</td>
</tr>
<tr>
<td>09.35</td>
<td>What’s new in management of bicuspid aortopathy?</td>
<td>09.50</td>
<td>Honorary lecture</td>
</tr>
<tr>
<td>10.50</td>
<td>Coffee break Ask to expert I (Nagelmackers room, Level 2)</td>
<td>10.05</td>
<td>Coffee break Ask to expert III (Nagelmackers room, Level 2)</td>
</tr>
<tr>
<td>11.30</td>
<td>Welcome address</td>
<td>10.35</td>
<td>Medical treatment of AAA</td>
</tr>
<tr>
<td>12.00</td>
<td>Keynote lecture</td>
<td>11.20</td>
<td>Keynote lecture</td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch break</td>
<td>12.00</td>
<td>TAVI</td>
</tr>
<tr>
<td>13.00</td>
<td>New insights in the aortic pathology</td>
<td>12.30</td>
<td>Experts panels</td>
</tr>
<tr>
<td>13.10</td>
<td>New insights from rodent models of aortic disease</td>
<td>13.30</td>
<td>Keynote lecture</td>
</tr>
<tr>
<td>13.40</td>
<td>Coffee break Ask to expert II (Nagelmackers room, Level 2)</td>
<td>13.45</td>
<td>EVAR &amp; TEVAR</td>
</tr>
<tr>
<td>14.15</td>
<td>The revised ascending aorta and aortic arch</td>
<td>14.15</td>
<td>Coffee break Ask to expert IV (Nagelmackers room, Level 2)</td>
</tr>
<tr>
<td>14.40</td>
<td>New insights from rodent models of aortic disease</td>
<td>15.30</td>
<td>Coffee break Ask to expert IV (Nagelmackers room, Level 2)</td>
</tr>
<tr>
<td>15.30</td>
<td>Coffee break Ask to expert II (Nagelmackers room, Level 2)</td>
<td>15.35</td>
<td>Coffee break Ask to expert IV (Nagelmackers room, Level 2)</td>
</tr>
<tr>
<td>16.00</td>
<td>Distal aortic dissection</td>
<td>16.05</td>
<td>Associations in aortic aneurysmal disease</td>
</tr>
<tr>
<td>16.20</td>
<td>Imaging of aortic diseases</td>
<td>17.15</td>
<td>Management of aortic graft infections</td>
</tr>
<tr>
<td>17.40</td>
<td>Radiation exposure</td>
<td>18.00</td>
<td>Proximal aortic dissection</td>
</tr>
<tr>
<td>18.30</td>
<td>End of the sessions</td>
<td>18.30</td>
<td>Awards ceremony and adjournment</td>
</tr>
<tr>
<td>19.10</td>
<td>End of the sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.00</td>
<td>Official dinner</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Wednesday September 12

13.00 Welcome address, Jean-Olivier Defraigne, Vincent D’Orio

New insights in the aortic pathology
Per Eriskon, Florence Pinet

13.10 Insights from transcriptomic and proteomic analysis of human aneurysmal cells, Florence Pinet
13.18 A mechanistic link between mechanical stress and inflammation in the progression of aortic diseases, Koichi Yoshimura
13.26 Predicting AAA growth and rupture with a skin biopsy, Kakkhee Yeung
13.34 A novel diagnostic score for AAA based on plasma D-dimer and myeloperoxidase, Wolf-Hans Eilenberg
13.42 Functional implications and therapeutic relevance of neutrophil extracellular traps in AAA, Christine Brostjan
13.50 Pathological remodeling of vascular smooth muscle in AAA: a therapeutic target? Marc Bailey
13.58 Novel biomarkers of AAA derived from genetic and epigenetic studies, Gregory Jones

14.06 Advanced glycation end products measured by skin autofluorescence are increased in patients with AAA, Clark J. Zeebregts
14.14 Precision medicine in thoracic aortic disease, Julie De Backer
14.22 Discussion

New insights from rodent models of aortic disease
Marc Bailey, Lars Maegdefessel

14.40 Critical review of the murine AAA models for 2018, Raphaël Coscas
14.48 3D ultrasound imaging of murine AAA, Marc Bailey
14.56 Anatomical modifications of the PPE model in mice, Albert Busch
15.04 Lessons learnt from the Guinea pig rat transplantation model of AAA, Eric Allaire
15.12 Therapeutic applications of prostaglandins and thromboxane A2 inhibitors in AAA, Audrey Courtois
15.20 Molecular pathways driving aortic disease in mouse models of ACTA2, MYLK, and MYH11 mutations, Dianna Milewicz
15.28 Discussion
15.50 Coffee break

Imaging of aortic diseases
Barry Doyle, Joy Roy

16.20 Quantification of abdominal aortic calcification: inherent measurement errors in current computed tomography imaging, Clark J. Zeebregts
16.28 The discrepancy between the non-automatic and semiautomatic measurement—does it influence outcome? Joy Roy
16.36 Biomechanical wall stress and rupture potential in AAA – data from the MA3RS Trial, Barry Doyle
16.44 Different AAA biomechanical rupture risk assessment approaches. Model fidelity versus diagnostic predictability, Christian Gasser
16.52 Computational biomechanics and morphology of small rAAA – a report from the STAR database, Rebecka Hultgren

17.00 IVUS and CO2 angiogram for aortic disease: strategy to minimize the use of contrast, Igor Sincos
17.08 Role of 3D printing in aortic surgery, Ramesh Tripathi
17.16 Discussion

Radiation exposure*
Anders Wanhainen

17.40 Strategies for optimal occupational radiation protection during vascular intervention, Bijan Modarai
17.48 Dose optimized imaging protocols to reduce radiation exposure during complex endovascular aortic repair, Thanos Katsargyris
17.56 Effect of MRI on human lymphocyte DNA: myth or reality? Alain Nchimi
18.04 Radiation protection in the endosuite and the importance of correct use of shields, Anders Wanhainen
18.12 Discussion

18.30 End of the sessions

* BELGIAN ATTENDEES – Radiologists, cardiologists and vascular surgeons

Thanks to our partnership with the AFCN (Agence Fédérale de Contrôle Nucléaire), the session on Radiation exposure on Wednesday September 12 at 17.40 can be valued as 1 hour of continuing education.
Thursday September 13

What's new in research on bicuspid aortopathy?
Simon Body, Bart Loeys
08.30 The complex genetic architecture of bicuspid aortic valve related aortopathy, Bart Loeys
08.38 Protein-altering and regulatory genetic variants near GATA4 implicated in BAV, Simon Body
08.46 New insights in the genetics of aortopathy and BAV in Turner syndrome, Aline Verstraeten
08.54 The current understanding about aortic wall disease mechanisms in BAV, Nimrat Grewal
09.02 Circulating microRNAs in bicuspid aortopathy, Evaldas Girdauskas
09.10 TGF-b/ENG ratio in bicuspid aortopathy, Alessandro Della Corte
09.18 Discussion

What's new in management of bicuspid aortopathy?
Alessandro Della Corte, Hector Michelena
09.35 Fluid dynamics simulations to understand BAV aortopathy mechanisms and risks, Luca Koechlin
09.43 Searching for early biomechanically-driven indexes of aortic remodeling: where are we at? Emiliano Votta
09.51 Advanced imaging biomarkers in bicuspid aortic valve disease surveillance, Malenka Bissell
09.59 Gender-related differences in bicuspid aortopathy history and outcomes, Hector Michaelsen
10.07 How does the current knowledge on BAV aortopathy impact valve repair? Alessandro Della Corte
10.15 Phenotype-guided surgical treatment of bicuspid aortopathy, Ruggero De Paulis
10.23 Discussion
10.50 Coffee break
Ask to expert I (Nagelmackers room – Level 2)
Place of the laparoscopy in the management of the Type 2 endoleaks, Nicos Labropoulos, Jean-Paul Lavigne
Short communication: unusual complication of IMA embolisation for type 2 endoleaks, Arnaud Kerzmann

TAVI
Patrizio Lancellotti, Thomas Modine
11.20 Overview on ongoing randomized clinical trials in TAVI, Patrizio Lancellotti
11.28 Is TAVR already arguable in low and moderate risk patients? Thomas Modine
11.36 Aortic regurgitation after TAVI - Can we do better? Joëlle Kefer
11.44 TAVI endocarditis, Bernard Jung
11.52 Experience from CHU Liège, Belgium, Christophe Martinez, Marc Radermecker
12.00 Percival (sutureless valve) indications at CHU Liège; a booster of the mini invasive aortic valve replacement program, Marc Radermecker
Keynote lecture
12.08 Aortic valve reconstruction using the Ozaki technique, when and in whom? Cesare Quarto
12.18 Discussion
12.30 Lunch break
Keynote lecture
Rodolphe Durieux
13.30 Open reoperations for complications of endovascular aortic procedures: top of the iceberg? Nicholas Kouchoukos

Experts panels
What is the aortic size threshold for TAA intervention?
Nicholas Kouchoukos, Patrizio Lancellotti, Dianna Milewicz, Christoph Nienaber
13.45 Should the criterion for surgical intervention for thoracic aortic aneurysm be moved “leftward” (earlier)? John Elefteriades
13.55 Lesson learned from local experiences in Liège with type A dissection, Natsi Sakalihasan
14.00 Discussion

The revised ascending aorta and aortic arch
Jean-Olivier Defraigne, John Elefteriades, N. Kouchoukos
14.15 Genetic basis of thoracic aortic disease and impact of altered gene on patient management, Dianna Milewicz
14.23 The z-score-misleading clinical science? John Elefteriades
14.31 Arch variants, Tilo Köbel
14.39 Surgery of the aortic arch nowadays, Nicholas Kouchoukos
14.47 Arch hybrid procedures are effective and durable for arch aneurysms, Colin Bicknell
14.55 Endo-treatment of arch and ascending aorta, Tilo Köbel
15.03 Discussion
15.30 Coffee break
Ask to expert II (Nagelmackers room – Level 2)
When and how to treat the primary aortic mural thrombus? Ramesh Tripathi
Case presentation: symptomatic ascending and asymptomatic thoraco-abdominal aortic thrombus, Arnaud Kerzmann
Thursday September 13

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>The conundrum about complicated and uncomplicated type B dissection - new concepts! Christoph Nienaber</td>
</tr>
<tr>
<td>16.08</td>
<td>When is a dissection to be called chronic and why? Firas Mussa</td>
</tr>
<tr>
<td>16.16</td>
<td>What is the role of tissue inflammation in dissection and how do we diagnose it? Natzi Sakalihasan</td>
</tr>
<tr>
<td>16.24</td>
<td>How can imaging tell us about the plasticity of a dissection? Biomechanical modelling and PET/CT in type B aortic dissection: development of the Perth-Liege risk score for TBAD, Barry Doyle</td>
</tr>
<tr>
<td>16.32</td>
<td>Temporal and morphological patterns predict outcome of endovascular repair in acute complicated type B aortic dissection, Rebecka Hultgren</td>
</tr>
<tr>
<td>16.40</td>
<td>Critical aortic dissections: benefit of surgical creativity out of any guidelines, Parla Astarci</td>
</tr>
<tr>
<td>16.48</td>
<td>Discussion</td>
</tr>
<tr>
<td>17.10</td>
<td>The role of biomarkers in the setting of acute aortic syndrome? Toru Suzuki</td>
</tr>
<tr>
<td>17.18</td>
<td>The integration of genetic testing in the work-up of a patient with aortic dissection, Bulat Ziganshin</td>
</tr>
<tr>
<td>17.26</td>
<td>Is pregnancy a risk for acute aortic dissection? Anselm Uebing</td>
</tr>
<tr>
<td>17.34</td>
<td>How to manage acute aortic dissection in pregnancy? John Elefteriades</td>
</tr>
<tr>
<td>17.42</td>
<td>Discussion</td>
</tr>
<tr>
<td>18.00</td>
<td>The role of false lumen intervention to promote remodeling via induced thrombosis, Christoph Nienaber</td>
</tr>
<tr>
<td>18.08</td>
<td>How much arch reconstruction is needed in type A aortic dissection? Ulrich Rosendahl</td>
</tr>
<tr>
<td>18.16</td>
<td>Inchng toward an endovascular solution for proximal dissection - will an Endo-Bentall see the light of day? Christoph Nienaber</td>
</tr>
<tr>
<td>18.24</td>
<td>Open surgery for aortic dissections, Nimesh Desai</td>
</tr>
<tr>
<td>18.32</td>
<td>Abdominal aortic open fenestration and other open surgical tricks: usefulness in type B dissections, Fabien Koskas</td>
</tr>
<tr>
<td>18.40</td>
<td>Optimised management of type A aortic dissection with visceral malperfusion - concept to reconsider, Mathias Thielmann</td>
</tr>
<tr>
<td>18.48</td>
<td>Discussion</td>
</tr>
<tr>
<td>19.10</td>
<td>End of the sessions</td>
</tr>
<tr>
<td>20.00</td>
<td>Official dinner</td>
</tr>
</tbody>
</table>

Official dinner

Thursday September 13, 20.00
Palais Provincial
All delegates are welcome to register with one guest. Seated dinner. Participation fee: 55 € per person.

Notes
Friday September 14

I Epidemiology and natural history of AAA
  Hans-Henning Eckstein, Rebecka Hultgren
08.30 When is the prevalence too low to motivate continued screening? Sverker Svensjö
08.38 The New Zealand AAA-specific risk scoring tool, Gregory Jones
08.46 Aneurysm rupture is not simply a mechanical event: how so and what are the implications? Rao Vallabhaneni
08.54 Female sex is not an independent risk factor for higher periprocedural mortality rates of AAAs - the nationwide Swedish DRG microdata from 2000-2016 on >50,000 cases, including socioeconomical aspects, Rebecka Hultgren
09.02 Why do women have higher operative mortality than men for aortic aneurysm repair? Janet Powell
09.10 Do all 25-29 mm ectatic aortas progress to AAAs actually needing repair? Sverker Svensjö
09.18 Discussion
09.42 Frank Lederle lectures, Ronald Dalman

10.05 Coffee break
Ask to expert III [Nagelmackers room – Level 2]

How can we avoid spinal cord ischemia during TEVAR/EVAR for Aortic aneurysms? Robin Heijmen, John Elefteriades
Case presentation: paraplesia, a rare complication of EVAR for AAA, Vincent Tchana-Sato

I Medical treatment of AAA
  Ronald Dalman, Anders Wanhainen
10.35 AAA: is there a role for the prevention and therapy using antioxidants? Joël Pincemail
10.45 Could metformin be a drug effective in limiting AAA growth and requirement for surgery: data from a large group of cohorts, Jonathan Golledge
10.55 Ticagrelor and the inhibition of growth in small AAAs – results from a RCT, Anders Wanhainen
11.05 The role of fish oil in the natural history of AAA, Jes Lindholt
11.15 Hormone replacement therapy and AAA - A HUNT study based on 20,000 women, Rebecka Hultgren
11.25 Role of resveratrol and the bone protein sclerostin in protection from AAA, Jonathan Golledge
11.35 Cipro and the aorta - Fluoroquinolone attack? Bulat Ziganshin
11.45 What diabetes can teach us about AAA? Ronald Dalman
11.55 Discussion

Keynote lecture
12.15 Prevention of the neurological complications, Robin Heijmen
12.30 Lunch break

I EVAR & TEVAR
  Colin Bicknell, Kakkhee Yeung
13.45 EVAR or open: what is the best option for patients and society? Jan Lindeman
13.53 The role of open surgery for AAA in the endovascular era, Franco Grego
14.01 The effect of clinical, psychosocial and socio-demographic variables on mental and physical functioning after vascular surgery, Colin Bicknell
14.09 The UK Complex Aneurysm Study: an overview, Rao Vallabhaneni
14.17 Endoleaks in EVAR, risk factors and prevention, Eric Allaire
14.25 Wide proximal aortic neck in the outcome of EVAR, Athanasios Giannoukas
14.33 Acute kidney injury after endovascular surgery: results from a pilot randomized controlled trial and a cohort study, Athanasios Saratzis
14.41 Importance of changes in thoracic and abdominal aortic stiffness following stent graft implantation, Christos Liapis
14.49 Prevention of stent graft migration after TEVAR: mathematical model, Lazar B. Davidovic
14.57 Results of endurant study (follow-up and comparison with Ace study), Jean-Pierre Becquemin
15.05 What do we know about AD risk factors for later problems? Jan Brunkwall
15.13 Discussion

15.30 Coffee break
Ask to expert IV [Nagelmackers room – Level 2]

Spinal cooling catheter: new concept in paraplesia prevention, John Elefteriades

I Associations in aortic aneurysmal disease
  Thomas Bilfinger, Nicos Labropoulos
16.05 Arterial aneurysms associated with the aorta, Nicos Labropoulos
16.13 Is AAA a risk factor for neoplasia? Natzi Sakalihasan
16.21 What is the association between AAA, hernia and simple renal cyst? Apostolos Tassiopoulos
16.29 Incidence of AAA is higher in the patients with COPD and smoking - why? Thomas Bilfinger
16.45 Cardiovascular risk management in patients with small AAA, Matthew Bown
16.53 Discussion
Friday September 14

Management of aortic graft infections
Rebecka Hultgren, Ramesh Tripathi

17.15 Is conservative management of graft infections justified? Ramesh Tripathi

17.23 Endovascular repair is effective in emergency but definitive excisional graft removal is the aim for all infected aortic grafts and endografts, Colin Bicknell

17.31 The place of allografts in the management of aortic graft infections, Evelyne Boesmans

17.39 Treatment of vascular infection with arterial homografts: 27 years of experience at European Homograft Bank (EHB) in Brussels, Ramadan Jashari

17.47 How to treat an infected aortic endograft by in-situ reconstruction with pericard tube grafts? Hans-Henning Eckstein

17.55 Discussion

18.30 Awards ceremony and adjournment
**General information**

**MEETING VENUE**
Les Comtes de Méan
Mont Saint Martin 9-11
Liège, Belgium
www.lescomtesdemean.be

**HOTELS**
1. Les Comtes de Méan*****(congress venue) Mont Saint Martin 9-11
   www.lescomtesdemean.be
2. Pentahotel Liège**** (5 min. walk)
   100, bd de la Sauvenière
   www.pentahotels.com

**REGISTRATION & INFORMATION DESK**
Wednesday .................. 12.00 - 19.00
Thursday ..................... 08.00 - 19.30
Friday ....................... 08.00 - 18.30

**EXHIBITION HOURS**
Wednesday .................. 12.00 - 19.00
Thursday ..................... 08.00 - 19.30
Friday ....................... 08.00 - 16.30

**SOCIAL EVENT**
IMAD Official dinner
Palais Provincial
Thursday, September 13, 20.00
All delegates are welcome to register with one guest.
Participation fee: 55€ per person.
Seated dinner.

**EXHIBITORS**

<table>
<thead>
<tr>
<th>Booth</th>
<th>Industrial</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>COOK MEDICAL</td>
</tr>
<tr>
<td>2</td>
<td>HOSPITHERA</td>
</tr>
<tr>
<td>3</td>
<td>ABBOTT MEDICAL BELGIUM</td>
</tr>
<tr>
<td>4</td>
<td>GETINGE</td>
</tr>
<tr>
<td>5</td>
<td>ETHICON</td>
</tr>
<tr>
<td>6</td>
<td>EDWARDS LIFESCIENCES</td>
</tr>
<tr>
<td>7</td>
<td>TERUMO EUROPE</td>
</tr>
<tr>
<td>8</td>
<td>PETERS SURGICAL</td>
</tr>
<tr>
<td>9</td>
<td>BARD</td>
</tr>
<tr>
<td>10</td>
<td>EUROSETS</td>
</tr>
<tr>
<td>11</td>
<td>MEDTRONIC</td>
</tr>
<tr>
<td>12</td>
<td>AORTA JOURNAL</td>
</tr>
<tr>
<td>13</td>
<td>LIVANOVA</td>
</tr>
</tbody>
</table>

**EVENT COORDINATORS’ CONTACTS**

Michèle Caboste
Individual registrations
Group/Sponsor reservations
Tel: +33 (0)4 91 57 19 66
mcaboste@divine-id.com

Cyrille Launoy
Faculty logistics
Mobile: +33 (0)6 73 53 45 89
claunoy@divine-id.com

Katy Chey
General organization
Tel: +33 (0)4 91 57 19 64
Mobile: +33 (0)6 13 96 08 70
kchey@divine-id.com

Véranne Bergeron Moreau
Executive manager
Tel: +33 (0)4 91 57 19 62
Mobile: +33 (0)6 21 78 87 16
vbergeron@divine-id.com

**LOCAL CONTACT**

Lindsay Smits
Scientific program
Tel: +32 (0)4 366 82 64
l.smits@chu.ulg.ac.be

---

**Level 1**

Exhibition hall
Auditorium
Registration desk
Access to lobby
Toilets
Exhibition hall
Buffet
Lifts
Level 1
Sponsors 2018

Gold sponsor

Medtronic

Silver sponsors

COOK MEDICAL
Edwards
HOSPITHERA

LivaNova
GETINGE

Bronze sponsors

Abbott
BD
BARD
EUROSETS
ETHICON

Peters Surgical
TERUMO Aortic

Other

IMAD 2018 is compliant with the Eucomed Code of Ethical Business Practice

IMAD 2018, Liège, Belgium, 12/09/2018-14/09/2018 has been granted 19 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education

8 EBCP recertification points

Mdeon Visa number: 18/V2/10562/005967

Scientific contact:
Dept of Cardiovascular & Thoracic Surgery • CHU Liège • 4000 Liège • Belgium
Tel.: +32 4 366 82 64 • Fax: +32 4 366 74 10 • Lindsay Smits l.smits@chu.ulg.ac.be

ORGANIZATION:
divine [id] agency ✴ Vérane Bergeron Moreau ✴ Katy Chey
kchey@divine-id.com ✴ 17, rue Venture ✴ 13001 Marseille ✴ France
Tel.: +33 (0) 491 57 19 60 ✴ Fax: +33 (0) 491 57 19 61 ✴ www.divine-id.com